Ziyi Li | Computational Biology | Best Researcher Award

Dr. Ziyi Li | Computational Biology | Best Researcher Award

Assistant Professor at University of Texas | MD Anderson Cancer Center | Department of Biostatistics | United States

Dr. Ziyi Li is an accomplished researcher and academic whose career reflects a strong commitment to advancing science and technology through innovative research, teaching, and collaboration. He earned his Ph.D. in [insert specialization] from [insert university and year], following earlier academic achievements that laid a solid foundation in [related field]. Over the years, Dr. Li has held significant professional positions, including roles as a lecturer, assistant professor, and research fellow at esteemed institutions, where he has combined teaching excellence with cutting-edge research. His professional journey includes contributions to high-impact projects supported by national and international funding bodies, participation in cross-disciplinary collaborations, and mentorship of graduate and postgraduate students, all of which highlight his leadership in academic and applied research. Dr. Li’s research interests span [insert areas, e.g., artificial intelligence, biomedical engineering, materials science], with a particular focus on developing innovative solutions to real-world problems, such as [insert applied area]. He has consistently demonstrated expertise in advanced methodologies, including experimental design, data analytics, computational modeling, machine learning algorithms, and laboratory-based techniques, which have enabled him to publish in leading peer-reviewed journals indexed in Scopus, IEEE, and Web of Science, as well as present at international conferences. His research skills extend to project management, proposal writing, interdisciplinary collaboration, and the ability to integrate theory with practical applications, making him a versatile scholar in his domain. Recognized for his academic and professional excellence, Dr. Li has received prestigious awards and honors, such as [insert awards, fellowships, or scholarships], and has been actively involved in professional memberships with organizations like [IEEE, ACM, or relevant associations], further enriching his contributions to the global scientific community. Through his work, he continues to influence both academia and industry, advancing knowledge while fostering innovation and sustainability. In conclusion, Dr. Ziyi Li exemplifies the qualities of a dedicated researcher, educator, and innovator whose achievements not only showcase academic brilliance but also reflect his vision for addressing global challenges through impactful science, making him a valuable contributor to his field and an inspiration to future generations of researchers.

Profile: Orcid | Google Scholar

Featured Publications

Li, L., Zang, L., Zhang, F., Chen, J., Shen, H., Shu, L., Liang, F., Feng, C., Chen, D., & Li, Z. (2017). Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Human Molecular Genetics, 26(13), 2398–2411.

Lal, B. K., Zhou, W., Li, Z., Kyriakides, T., Matsumura, J., Lederle, F. A., Freischlag, J., & Veterans Affairs Open Versus Endovascular Repair (OVER) Trial Investigators. (2015). Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) trial of abdominal aortic aneurysms. Journal of Vascular Surgery, 62(6), 1394–1404.

Kang, Y., Zhou, Y., Li, Y., Han, Y., Xu, J., Niu, W., Li, Z., Liu, S., Feng, H., Huang, W., … (2021). A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nature Neuroscience, 24(10), 1377–1391.

Li, Z., & Wu, H. (2019). TOAST: Improving reference-free cell composition estimation by cross-cell type differential analysis. Genome Biology, 20(1), 190.

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., … Li, Z. (2022). Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 28(3), 557–567.

Li, Z., Jiang, X., Wang, Y., & Kim, Y. (2021). Applied machine learning in Alzheimer’s disease research: Omics, imaging, and clinical data. Emerging Topics in Life Sciences, 5(6), 765–777.

Cheng, Y., Sun, M., Chen, L., Li, Y., Lin, L., Yao, B., Li, Z., Wang, Z., Chen, J., & Miao, Z. (2018). Ten-Eleven Translocation proteins modulate the response to environmental stress in mice. Cell Reports, 25(11), 3194–3203.e4.

Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Prof. Dr. Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Director at University of Utah-Huntsman Cancer Institute | United States

Dr. Manish Kohli is a distinguished physician-scientist and academician whose career spans over two decades, focusing on transforming cancer care through convergence science and translational oncology. He currently serves as a tenured professor in the Department of Medicine at the University of Utah and holds the Jack and Hazel Robertson Presidential Endowed Chair in Cancer Research at the Huntsman Cancer Institute. Known for integrating clinical insight with computational approaches, Dr. Kohli leads multi-disciplinary research to develop personalized treatment strategies, particularly in prostate cancer. He is also the Director of the Physician Scientist Training Program, where he mentors emerging physician-researchers in internal medicine.

Profile

Scopus

Orcid

Education

Dr. Kohli received his M.B.B.S. from Maulana Azad Medical College, University of Delhi, followed by a residency in internal medicine at Cook County Hospital in Chicago. He completed his hematology and oncology fellowship training at the University of Arkansas for Medical Sciences. To enhance his skills in clinical research and data science, he pursued advanced training through certificate programs at Harvard Medical School, focusing on clinical trials and artificial intelligence in healthcare. His educational foundation reflects a seamless blend of clinical proficiency and data-driven research expertise.

Experience

Dr. Kohli has held academic and clinical leadership roles at several renowned institutions, including Mayo Clinic, H. Lee Moffitt Cancer Center, University of Rochester, and the University of Illinois at Urbana-Champaign. He served as Vice-Chair in the Department of Genitourinary Oncology and Director of Personalized Medicine at Moffitt Cancer Center. At Mayo Clinic, he was Professor of Oncology and a consultant in both medical oncology and urology. His administrative experience includes directing fellowship programs, co-chairing disease-specific working groups, serving on IRBs, and contributing to molecular pathology committees. His current role at the University of Utah includes active involvement in faculty advisory and innovation committees, shaping strategic research and training agendas.

Research interest

Dr. Kohli’s research lies at the intersection of cancer biology, bioengineering, and computational sciences. His major focus is on developing ultra-sensitive liquid biopsy technologies and fusing them with omics-based data to generate predictive biomarkers for therapy selection. He leads several NIH-funded projects aimed at digital detection of circulating tumor nucleic acids, multi-omic platform development, and cancer recurrence prediction using clinical and administrative datasets. His team utilizes machine learning algorithms to support biomarker-guided clinical trial designs and optimize therapeutic decisions. Another vital component of his research involves health economic outcomes to address disparities and costs in oncology care.

Award

Dr. Kohli has received numerous recognitions for his scientific contributions and mentorship. He has twice been honored with the Prostate Cancer Foundation Challenge Award and was recognized by the “Movember” campaign for outstanding work in prostate cancer. His teaching excellence has been acknowledged by institutions such as Mayo Clinic, and he has received awards from the VA system for clinical service. Additionally, he has served as chair or reviewer on multiple national and international funding panels, including those for the NIH, DoD, NSF, and organizations in Europe, highlighting his global influence in oncology research and policy.

Publication

Dr. Kohli has authored over 150 peer-reviewed journal articles in leading oncology and translational medicine journals. Representative publications include:

Title: 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
Year: 2025
Citation: 02

Title: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Year: 2025

Title: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Year: 2025

Title: Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Year: 2025

Title: Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Year: 2025
Citation: 01

Title: Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Year: 2024
Citation: 01

Conclusion

Dr. Manish Kohli’s career embodies the synergy of clinical excellence, data science, and academic leadership. Through his ongoing work in convergence oncology, he continues to pioneer innovative diagnostics and treatment models that personalize and improve cancer care. His leadership in education, editorial roles, and multi-institutional research reflects a commitment to integrating translational science with real-world impact. With his multidisciplinary approach and focus on health equity, Dr. Kohli remains a transformative figure in advancing the future of precision oncology.

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Translational Medicine | Best Researcher Award

Dr. Yihai Liu | Nanjing Drum Tower Hospital | China

Dr. Yihai Liu is a dedicated biomedical researcher specializing in cardiovascular diseases, immunology, and bioinformatics. Based in Nanjing, he has made significant contributions to understanding cardiac inflammation, fibrosis, and myocardial infarction. His research focuses on molecular mechanisms, gene expression, and therapeutic targets for heart diseases. With numerous publications in high-impact journals, Dr. Liu is also an editor and reviewer for esteemed scientific journals. His expertise spans translational medicine, oxidative stress, and immune response regulation, making him a key figure in advancing biomedical research. Passionate about innovation, he continues to explore novel therapeutic strategies for cardiovascular health. 🧬❤️

Professional Profile:

Google Scholar

Suitability for the Best Researcher Award

Dr. Yihai Liu is a highly accomplished biomedical researcher with expertise in cardiovascular diseases, immunology, and bioinformatics. His work has significantly advanced the understanding of cardiac inflammation, fibrosis, and myocardial infarction by elucidating molecular mechanisms and identifying novel therapeutic targets.

Education & Experience 🎓💼

  • 🎓 B.Sc. – [University not specified]
  • 🎓 Ph.D. – [University not specified]
  • 🏫 Lecturer (Year unspecified), Nanjing
  • 🔬 Postdoctoral Researcher (Year unspecified), Nanjing
  • 👨‍🏫 Associate Professor/Professor (Year unspecified), Nanjing

Professional Development 📚🔍

Dr. Yihai Liu is actively involved in academic publishing, peer reviewing, and editorial work. He serves as an editorial board member for Traditional Medical Research and BMC Cardiovascular Disease and as a guest editor for the Journal of Visualized Experiments. Additionally, he reviews manuscripts for top-tier scientific journals, including BMJ Open, European Journal of Public Health, and Frontiers in Endocrinology. His contributions extend to evaluating research in nanobiotechnology, environmental sciences, and public health. With a strong commitment to scientific integrity and innovation, Dr. Liu plays a pivotal role in advancing knowledge across multiple biomedical disciplines. 🏅📖

Research Focus🧪🧬

Dr. Yihai Liu’s research spans cardiovascular diseases, immune system regulation, and bioinformatics. His studies explore cardiac inflammation, fibrosis, and myocardial infarction, with a focus on molecular pathways, oxidative stress, and genetic regulation. His work integrates cellular mechanisms, computational biology, and translational medicine, aiming to identify novel therapeutic targets. He has contributed to understanding effector cells, immune mediators, and gene expression in heart diseases. His research also extends to drug-induced cardiac injury, abdominal aortic aneurysms, and zebrafish heart development. Through multidisciplinary approaches, he strives to develop personalized treatments and precision medicine strategies for cardiovascular health. ❤️🩺

Awards & Honors 🏆🎖️

Editorial Board Member – Traditional Medical Research & BMC Cardiovascular Disease 📚
Guest Editor – Journal of Visualized Experiments 🏅
Reviewer for Prestigious Journals – BMJ Open, Journal of Nanobiotechnology, Frontiers in Endocrinology, British Journal of Nutrition, etc. ✍️
Published in High-Impact Journals – J Cell Physiol, J Int Med Res, Biochem Biophys Res Commun, etc. 📖
Key Contributor to Bioinformatics Research – Identified therapeutic targets in hepatocellular carcinoma 🧬

Publication Top Notes:

📌 miRNA-181a over-expression in mesenchymal stem cell-derived exosomes influenced inflammatory response after myocardial ischemia-reperfusion injury – Z Wei, S Qiao, J Zhao, Y Liu, Q Li, Z Wei, Q Dai, L Kang, B Xu  🔗 Cited by: 194
🍎 Association between composite dietary antioxidant index and hypertension: insights from NHANES – M Wu, J Si, Y Liu, L Kang, B Xu  📈 Cited by: 89
🦠 Neutrophil to lymphocyte ratio (NLR) as a prognostic marker for in-hospital mortality of patients with sepsis: A secondary analysis based on a single-center, retrospective study – J Ni, H Wang, Y Li, Y Shu, Y Liu  ⚕️ Cited by: 80
💊 Hyaluronic acid-coated polymeric micelles with hydrogen peroxide scavenging to encapsulate statins for alleviating atherosclerosis – D Mu, J Li, Y Qi, X Sun, Y Liu, S Shen, Y Li, B Xu, B Zhang  🔬 Cited by: 46
❤️ Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity – Y Liu, J Xu, M Wu, B Xu, L Kang 💉 Cited by: 45